Nutex Health Inc
$ 179.15
-2.59%
13 Jul - close price
- Market Cap 1,265,547,000 USD
- Current Price $ 179.15
- High / Low $ 187.00 / 175.08
- Stock P/E 13.46
- Book Value 49.81
- EPS 13.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.29 %
- ROE 0.54 %
- 52 Week High 204.00
- 52 Week Low 77.21
About
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Analyst Target Price
$246.40
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-05 | 2025-10-22 | 2025-06-30 | 2025-05-13 | 2025-03-31 | 2024-11-08 | 2024-08-08 | 2024-05-08 | 2024-03-28 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 5.74 | 1.62 | 7.76 | 5.2262 | 2.56 | 11.12 | -0.32 | -0.15 | -0.06 | -7.5 | -1.25 | -1.5 |
| Estimated EPS | 5.56 | 5.5567 | 1.81 | -5.43 | 1.62 | -0.1233 | 0.28 | -0.29 | None | -0.005 | -1.5 | -1.5 |
| Surprise | 0.18 | -3.9367 | 5.95 | 10.6562 | 0.94 | 11.2433 | -0.6 | 0.14 | 0 | -7.495 | 0.25 | 0 |
| Surprise Percentage | 3.2374% | -70.846% | 328.7293% | 196.2468% | 58.0247% | 9118.6537% | -214.2857% | 48.2759% | None% | -149900% | 16.6667% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NUTX
2026-07-13 20:40:26
This article announces the filing of Form PRE 14A by Nutex Health Inc. on July 13. The brief announcement provides no further details on the content of the filing but includes general market data.
2026-07-13 13:00:00
This article from Stock Traders Daily analyzes Nutex Health Inc. (NASDAQ: NUTX), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report also emphasizes a significant 78.7:1 risk-reward short setup for NUTX.
2026-07-10 00:41:17
Nutex Health's microhospital model, leveraging No Surprises Act arbitration, has significantly boosted revenue and profits. While this approach has driven financial success, it also exposes the company to risks associated with potential changes in arbitration rules and payer behavior. Despite rapid profit growth and a projected 28% upside to its fair value, some analysts remain cautious about the long-term durability of this arbitration-dependent model, highlighting the divergent opinions on Nutex's investment narrative.
2026-07-09 00:10:42
Nutex Health (NUTX) recently announced a significant increase in revenue and profits, attributed to its microhospital model utilizing No Surprises Act arbitration. This arbitration-driven success shifts the company's economics, making reimbursement outcomes crucial alongside traditional growth factors. The article explores how this strategy impacts Nutex's investment narrative, highlighting both opportunities from rapid profit growth and risks associated with potential changes in arbitration rules or payer pushback.
2026-07-04 17:40:14
This article provides a detailed financial overview for Nutex Health Inc. (NUTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also presents performance metrics such as year-to-date and yearly performance, along with analyst recommendations and a target price of $246.40.
2026-07-02 13:39:52
Nutex Health Inc. (NUTX) stock reached a 52-week high of $193.07 and is currently trading near $199.96, reflecting a 56% one-year return and recent gains of 28% in the past week and 29% over six months. Despite the rally, InvestingPro analysis suggests the stock might still be undervalued, with B.Riley initiating coverage with a Buy rating and a $290.00 price target. The company reported a 2.2% revenue increase to $216.5 million in Q1 2026, though adjusted EBITDA declined due to arbitration costs.
